Multi-Disciplinary Organization Dedicated to Promoting Advances in
Neuro-Oncology Through Research and Education

WFNOS Magazine

The inaugural issue of the official publication of the World Federation of Neuro-Oncology Societies is ...

Read Full Story

Neuro-Oncology Review Course at SNO

November 16, 2016. Register in conjunction with the SNO Annual Meeting

Read Full Story

CNS Anticancer Drug Discovery and Development Conference

Register Now!

Read Full Story
View All News

October
12

EANO 2016

Read Full Story

October
22

18th Annual Brain Tumor Update and 7th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine

Read Full Story

November
16

2nd CNS Anticancer Drug Discovery/Development Conference

Read Full Story

SNO Course on the Basics of Biomarkers 2012

SNO Course on the Basics of Biomarkers 2012
November 15, 2012
Washington, DC, Hilton Hotel
Course directors: Susan Chang and Kenneth Aldape
 
 
 
 
NIH has defined a biomarker as “an objectively measured indicator of a biological or pathobiological process”.  There are many potential areas for which biomarkers can improve patient care that range from early detection and diagnosis, prediction of response or toxicity of therapy, and prognosis.  Biomarkers can also potentially improve the efficiency of the development of novel treatment approaches.  Despite years of research and numerous reports however, the number of markers that have emerged as clinically useful has been limited. 
 
Many early reports of “promising biomarkers” are often not replicated in larger subsequent studies. In this course, we review the definition and potential roles of biomarkers as it pertains to Neuro-Oncology, the various types of biomarkers, the importance of biostatistical considerations in the development and validation of biomarkers, application of biomarkers in drug development, clinical application of biomarkers including their role in the use of anti-angiogenic treatments and future directions.
 
The course will be 2 hours and 25 minutes in length and will take place in the afternoon of Thursday, November 15, 2012, at the end of the regular Education Day sessions on targeted therapies. 
 
 
 
Topic
Presenter
Comments
Time allotted
Overview of biomarkers
Martin VandenBent
Potential roles of biomarkers in Neuro-Oncology- diagnosis and classification, predictive value (response and toxicity), prognostic value
Types of biomarkers
15 min presentation
5 min discussion
Imaging Biomarkers
Whitney Pope
Overview of imaging parameters that may serve as biomarkers
15 min presentation
5 min discussion
Biomarker development and validation from a biostatistical perspective
Annette Molinaro
The importance of statistical considerations in the development and validation of biomarkers
20 min presentation
5 min discussion
Translating findings from TCGA into clinical biomarkers
Jason Huse
Overview of results of the TCGA effort and its translational value with respect to biomarkers
15 min presentation,
5 min discussion
Biomarkers and antiangiogenic therapy
 
Manish Aghi
Overview of challenges, current status and future strategies
15 min presentation,
5 min discussion
Biomarker driven early clinical trials and the potential role in drug development
David Reardon
How biomarkers can be integrated into drug development and early clinical trials
15 min presentation,
5 min discussion
Biomarkers and clinical care- are we there yet?
Michael Weller
An overview of the integration of biomarkers into the care of the brain tumor patient
15 min presentation,
5 min discussion
 
 
SNO thanks the National Brain Tumor Society
for their generous support of this special session